-+ 0.00%
-+ 0.00%
-+ 0.00%

Sonnet BioTherapeutics Holdings Announces Safety Results Of Son-1010 At Highest Dose Combined With Atezolizumab In Phase 1b/2a Clinical Trial In Adult Patients With Advanced Solid Tumors Or Platinum-resistant Ovarian Cancer

Benzinga·04/04/2025 13:05:39
Listen to the news

Topline safety data in SB221 study suggest clinical benefit of SON-1010 in combination with atezolizumab (Tecentriq®)

The maximum tolerated dose (MTD) of SON-1010 was set at 1200 ng/kg in combination with atezolizumab in patients with platinum-resistant ovarian cancer (PROC), without dose-limiting toxicity or evidence of cytokine release syndrome at any dose level

Stable disease (SD) at four months post-initiation of dosing was seen in 5 of 15 evaluable patients (33%), with 4 continuing beyond 6 months

One patient with PROC who was dosed at the MTD had a partial response (PR) by RECIST criteria (44% decrease from baseline) and >2x decrease in the CA 125 biomarker